Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology

International Journal of Cardiology

Volumn 162, Issue 2, 2013, Pages 73-76

  Anker, Markus S ^a   Von Haehling, Stephan ^b   Springer, Jochen ^c   Banach, MacIej ^d   Anker, Stefan D ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cachexia; Cardiovascular illness; Heart failure; Keywords; Mechanism; Muscle wasting; Sarcopenia; Therapy

Indexed keywords

ANABOLIC AGENT; ANAMORELIN; ANTIOXIDANT; BL 6020 979; CARDIOVASCULAR AGENT; CARNITINE; CELECOXIB; ENOBOSARM; GHRELIN; HORMONE RECEPTOR BLOCKING AGENT; ICOSAPENTAENOIC ACID; IMIDAPRIL; MEGESTROL ACETATE; MELANOCORTIN 4 RECEPTOR; MT 102; MYOSTATIN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SOMATOMEDIN; TESTOSTERONE; UNCLASSIFIED DRUG; BILE ACID; CREATININE; DESMIN; SIRTUIN 1; ZINC;

CACHEXIA; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIET SUPPLEMENTATION; EXERCISE; HEART FAILURE; HUMAN; LEAN BODY WEIGHT; LIPOLYSIS; MUSCLE ATROPHY; MUSCLE STRENGTH; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; CARDIOLOGY; COMORBIDITY; CONSENSUS DEVELOPMENT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; HEART EJECTION FRACTION; KINESIOTHERAPY; MEDICAL LITERATURE; MEDICAL RESEARCH; NUTRITIONAL SUPPORT; PROTEIN TARGETING; PUBLICATION; SARCOPENIA; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

BIOMEDICAL RESEARCH; CACHEXIA; CARDIOVASCULAR DISEASES; GHRELIN; HUMANS; LIPOLYSIS; MUSCULAR ATROPHY; SARCOPENIA;

EID: 84870710669     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.10.018     Document Type: Review

References (105)

1. R.N. Baumgartner, K.M. Koehler, and D. Gallagher Epidemiology of sarcopenia among the elderly in New Mexico Am J Epidemiol 147 1998 755 763
2. I. Janssen, S.B. Heymsfield, and R. Ross Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability J Am Geriatr Soc 50 2002 889 896
3. I. Janssen Influence of sarcopenia on the development of physical disability: the cardiovascular health study J Am Geriatr Soc 54 2006 56 62
4. Y. Rolland, V. Lauwers-Cances, and M. Cournot Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study J Am Geriatr Soc 51 2003 1120 1124
5. F. Lauretani, C.R. Russo, and S. Bandinelli Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia J Appl Physiol 95 2003 1851 1860
6. J. Lees Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre Eur J Cancer Care 8 1999 133 136
7. W.D. Dewys, C. Begg, and P.T. Lavin Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group Am J Med 69 1980 491 497
8. J. Bachmann, M. Heiligensetzer, H. Krakowski-Roosen, M.W. Büchler, H. Friess, and M.E. Martignoni Cachexia worsens prognosis in patients with resectable pancreatic cancer J Gastrointest Surg 12 2008 1193 1201
9. S.D. Anker, P. Ponikowski, and S. Varney Wasting as independent risk factor for mortality in chronic heart failure Lancet 349 1997 1050 1053
10. R.H. Mak, and W. Cheung Energy homeostasis and cachexia in chronic kidney disease Pediatr Nephrol 21 2006 1807 1814
11. F. Koehler, W. Doehner, S. Hoernig, C. Witt, S.D. Anker, and M. John Anorexia in chronic obstructive pulmonary disease - association to cachexia and hormonal derangement Int J Cardiol 119 2007 83 89
12. M.A. Vermeeren, E.C. Creutzberg, and A.M. Schols Prevalence of nutritional depletion in a large out-patient population of patients with COPD Respir Med 100 2006 1349 1355
13. D.O. Wilson, R.M. Rogers, E.C. Wright, and N.R. Anthonisen Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial Am Rev Respir Dis 139 1989 1435 1438
14. A.M. Schols, P.B. Soeters, A.M. Dingemans, R. Mostert, P.J. Frantzen, and E.F. Wouters Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation Am Rev Respir Dis 147 1993 1151 1156
15. A.C. Elkan, N. Håkansson, J. Frostegård, T. Cederholm, and I. Hafström Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study Arthritis Res Ther 11 2009 R37
16. R. Roubenoff, R.A. Roubenoff, L.M. Ward, S.M. Holland, and D.B. Hellmann Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor J Rheumatol 19 1992 1505 1510
17. S. von Haehling, J.E. Morley, and S.D. Anker An overview of sarcopenia: facts and numbers on prevalence and clinical impact J Cachexia Sarcopenia Muscle 1 2010 129 133
18. S. von Haehling, and S.D. Anker Cachexia as a major underestimated and unmet medical need: facts and numbers J Cachexia Sarcopenia Muscle 1 2010 1 5
19. N. Scherbakov, and W. Doehner Sarcopenia in stroke - facts and numbers on muscle loss accounting for disability after stroke J Cachexia Sarcopenia Muscle 2 2011 5 8
20. D. Scott, L. Blizzard, J. Fell, and G. Jones The epidemiology of sarcopenia in community living older adults: what role does lifestyle play? J Cachexia Sarcopenia Muscle 2 2011 125 134
21. S. Dodson, V.E. Baracos, and A. Jatoi Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies Annu Rev Med 62 2011 265 279
22. S. von Haehling, M. Lainscak, J. Springer, and S.D. Anker Cardiac cachexia: a systematic overview Pharmacol Ther 121 2009 227 252
23. A.H. Remels, H.R. Gosker, R.C. Langen, and A.M. Schols The mechanisms of cachexia underlying muscle dysfunction in COPD J Appl Physiol 2012 10.1152/japplphysiol.00790.2012
24. K. Lenk, G. Schuler, and V. Adams Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training J Cachexia Sarcopenia Muscle 1 2010 9 21
25. M. Banach, and J. Rysz Current problems in hypertension and nephrology Expert Opin Pharmacother 11 2010 2575 2578
26. R.D. Kilgour, A. Vigano, and B. Trutschnigg Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer J Cachexia Sarcopenia Muscle 1 2010 177 185
27. T.P. Braun, and D.L. Marks Pathophysiology and treatment of inflammatory anorexia in chronic disease J Cachexia Sarcopenia Muscle 1 2010 135 145
28. L. Santarpia, F. Contaldo, and F. Pasanisi Nutritional screening and early treatment of malnutrition in cancer patients J Cachexia Sarcopenia Muscle 2 2011 27 35
29. F.S. Dioguardi Clinical use of amino acids as dietary supplement: pros and cons J Cachexia Sarcopenia Muscle 2 2011 75 80
30. T. Akamizu, and K. Kangawa Ghrelin for cachexia J Cachexia Sarcopenia Muscle 1 2010 169 176
31. R. Silvério, A. Laviano, F. Rossi Fanelli, and M. Seelaender l-Carnitine and cancer cachexia: clinical and experimental aspects J Cachexia Sarcopenia Muscle 2 2011 37 44
32. R. Dallmann, P. Weyermann, and C. Anklin The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia J Cachexia Sarcopenia Muscle 2 2011 163 174
33. K. Trobec, S. von Haehling, S.D. Anker, and M. Lainscak Growth hormone, insulin-like growth factor 1, and insulin signaling - a pharmacological target in body wasting and cachexia J Cachexia Sarcopenia Muscle 2 2011 191 200
34. J.C. Schefold, J. Bierbrauer, and S. Weber-Carstens Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock J Cachexia Sarcopenia Muscle 1 2010 147 157
35. M. Lainscak, S. von Haehling, and W. Doehner Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease J Cachexia Sarcopenia Muscle 2 2011 81 86
36. Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur Heart J in press.
37. R.H. Mak, A.T. Ikizler, C.P. Kovesdy, D.S. Raj, P. Stenvinkel, and K. Kalantar-Zadeh Wasting in chronic kidney disease J Cachexia Sarcopenia Muscle 2 2011 9 25
38. J. Malyszko, H. Bachorzewska-Gajewska, J. Malyszko, N. Iaina-Levin, G. Kobus, and S. Dobrzycki Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate Arch Med Sci 7 2011 658 664
39. M. Barylski, J. Małyszko, J. Rysz, M. Myśliwiec, and M. Banach Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 7 2011 1055 1066
40. M. Cicoira, S.D. Anker, and C. Ronco Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle J Cachexia Sarcopenia Muscle 2 2011 135 142
41. J. Malyszko, E. Zbroch, J. Malyszko, M. Mysliwiec, and A. Iaina The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients Arch Med Sci 6 2010 539 544
42. W.G. Couser, and M.C. Riella World Kidney Day 2011 - protect your kidneys, save your heart Arch Med Sci 7 2011 1 4
43. T. Kung, T. Szabó, J. Springer, W. Doehner, S.D. Anker, and S. von Haehling Cachexia in heart disease: highlights from the ESC 2010 J Cachexia Sarcopenia Muscle 2 2011 63 69
44. S. von Haehling, M. Lainscak, and W. Doehner Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) J Cachexia Sarcopenia Muscle 1 2010 187 194
45. M. Uematsu, Y.J. Akashi, and K. Ashikaga Association between heart rate at rest and myocardial perfusion in patients with acute myocardial infarction undergoing cardiac rehabilitation - a pilot study Arch Med Sci 8 2012 622 630
46. Y. Elkina, S. von Haehling, S.D. Anker, and J. Springer The role of myostatin in muscle wasting: an overview J Cachexia Sarcopenia Muscle 2 2011 143 151
47. S. Gielen, M. Sandri, and I. Kozarez Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging Catabolism Study Circulation 125 2012 2716 2727
48. M.J. Sullivan-Gunn, S.P. Campbell-O'Sullivan, M.J. Tisdale, and P.A. Lewandowski Decreased NADPH oxidase expression and antioxidant activity in cachectic skeletal muscle J Cachexia Sarcopenia Muscle 2 2011 181 188
49. A. Tschirner, S. von Haehling, S. Palus, W. Doehner, S.D. Anker, and J. Springer Ursodeoxycholic acid treatment in a rat model of cancer cachexia J Cachexia Sarcopenia Muscle 3 2012 31 36
50. S. von Haehling, J.C. Schefold, and E.A. Jankowska Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial J Am Coll Cardiol 59 2012 585 592
51. G. Ulubay, S.S. Ulasli, S.S. Bozbas, T. Ozdemirel, and M. Karatas Effects of peripheral neuropathy on exercise capacity and quality of life in patients with chronic obstructive pulmonary diseases Arch Med Sci 8 2012 296 302
52. S.D. Anker, T.P. Chua, and P. Ponikowski Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia Circulation 96 1997 526 534
53. E.A. Jankowska, G. Filippatos, and B. Ponikowska Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure J Card Fail 15 2009 442 450
54. E.A. Jankowska, B. Biel, and J. Majda Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival Circulation 114 2006 1829 1837
55. M. Toledo, S. Busquets, E. Ametller, F.J. López-Soriano, and J.M. Argilés Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration? J Cachexia Sarcopenia Muscle 2 2011 57 62
56. D.W. Russ, and J.S. Grandy Increased desmin expression in hindlimb muscles of aging rats J Cachexia Sarcopenia Muscle 2 2011 175 180
57. P.M. Siren, and M.J. Siren Systemic zinc redistribution and dyshomeostasis in cancer cachexia J Cachexia Sarcopenia Muscle 1 2010 23 33
58. S. Seneff, G. Wainwright, and L. Mascitelli Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet? Arch Med Sci 7 2011 8 20
59. A.M. Abbatecola, G. Paolisso, and P. Fattoretti Discovering pathways of sarcopenia in older adults: a role for insulin resistance on mitochondria dysfunction J Nutr Health Aging 15 2011 890 895
60. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol in press. http://dx.doi.org/10.1016/j. ijcard.2012.01.013.
61. V.G. Athyros, O. Giouleme, and E.S. Ganotakis Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study Arch Med Sci 7 2011 796 805
62. S.M. Gehrig, C. van der Poel, and T.A. Sayer Hsp72 preserves muscle function and slows progression of severe muscular dystrophy Nature 484 2012 394 398
63. P.M. Gilbert, K.L. Havenstrite, and K.E. Magnusson Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture Science 329 2010 1078 1081
64. A. Sacco, F. Mourkioti, and R. Tran Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice Cell 143 2010 1059 1071
65. N.A. Stephens, R.J. Skipworth, A.J. Macdonald, C.A. Greig, J.A. Ross, and K.C. Fearon Intramyocellular lipid droplets increase with progression of cachexia in cancer patients J Cachexia Sarcopenia Muscle 2 2011 111 117
66. S.K. Das, S. Eder, and S. Schauer Adipose triglyceride lipase contributes to cancer-associated cachexia Science 333 2011 233 238
67. P. Arner Medicine. Lipases in cachexia Science 333 2011 163 164
68. K.C. Fearon Cancer cachexia and fat-muscle physiology N Engl J Med 365 2011 565 567
69. B. Pajak, S. Orzechowska, and B. Pijet Crossroads of cytokine signaling - the chase to stop muscle cachexia J Physiol Pharmacol 59 Suppl. 9 2008 251 264
70. F. Chen, R. Lam, and D. Shaywitz Evaluation of early biomarkers of muscle anabolic response to testosterone J Cachexia Sarcopenia Muscle 2 2011 45 56
71. A. Gluba, A. Bielecka, and D.P. Mikhailidis An update on biomarkers of heart failure in hypertensive patients J Hypertens 30 2012 1681 1689
72. Patel SS, Molnar MZ, Tayek JA, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle in press. http://dx.doi.org/10.1007/s13539-012-0079-1.
73. Hettwer S, Dahinden P, Kucsera S, et al. Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients. Exp Gerontol in press http://dx.doi.org/10.1016/j.exger.2012.03.002.
74. M. Cesari, R.A. Fielding, and M. Pahor Biomarkers of sarcopenia in clinical trials - recommendations from the International Working Group on Sarcopenia J Cachexia Sarcopenia Muscle 3 2012 181 190
75. K. Schmidt, S. von Haehling, W. Doehner, S. Palus, S.D. Anker, and J. Springer IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia J Cachexia Sarcopenia Muscle 2 2011 105 109
76. T.D. Müller, D. Perez-Tilve, J. Tong, P.T. Pfluger, and M.H. Tschöp Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia J Cachexia Sarcopenia Muscle 1 2010 159 167
77. M. Stepien, K. Rosniak-Bak, and M. Paradowski Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results Med Sci Monit 17 2011 PR13 PR18
78. J.F. Yarrow, S.C. McCoy, and S.E. Borst Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): a potent anabolic steroid with reduced androgenic and estrogenic activity Steroids 75 2010 377 389
79. X. Zhou, J.L. Wang, and J. Lu Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival Cell 142 2010 531 543
80. J.C. Peter, H. Rossez, and M. Weckering Protective effects of an anti-melanocortin-4 receptor scFv derivative in lipopolysaccharide-induced cachexia in rats J Cachexia Sarcopenia Muscle 2012 [Epub ahead of print, PMID: 22911214]
81. S. von Haehling, R. Stepney, and S.D. Anker Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference Int J Cardiol 144 2010 347 349
82. J.M. Scarlett, D.D. Bowe, X. Zhu, A.K. Batra, W.F. Grant, and D.L. Marks Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure J Endocrinol 206 2010 121 130
83. C.J. Malkin, K.S. Channer, and T.H. Jones Testosterone and heart failure Curr Opin Endocrinol Diabetes Obes 17 2010 262 268
84. T. Thum, and J. Springer Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! J Cachexia Sarcopenia Muscle 2 Sep 2011 121 123
85. J.T. Dalton, K.G. Barnette, and C.E. Bohl The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial J Cachexia Sarcopenia Muscle 2 2011 153 161
86. http://www.clinicaltrials.gov [ NCT01355497 & NCT01355484 ]
87. http://www.clinicaltrials.gov [ NCT01387269 & NCT01387282 ]
88. A.J. Stewart Coats, V. Srinivasan, and J. Surendran The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design J Cachexia Sarcopenia Muscle 2 2011 201 207
89. N. Schanze, and J. Springer Evidence for an effect of ACE inhibitors on cancer cachexia J Cachexia Sarcopenia Muscle 3 2012 139
90. F. Penna, S. Busquets, and F. Pin Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise J Cachexia Sarcopenia Muscle 2 2011 95 104
91. S. von Haehling The muscle in dire straits: mechanisms of wasting in heart failure Circulation 125 2012 2686 2688
92. A. Macciò, C. Madeddu, and G. Gramignano A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life Gynecol Oncol 124 2012 417 425
93. C. Madeddu, M. Dessì, and F. Panzone Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome Clin Nutr 31 2012 176 182
94. P. Rozentryt, S. von Haehling, and M. Lainscak The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study J Cachexia Sarcopenia Muscle 1 2010 35 42
95. W.J. Evans, J.E. Morley, and J. Argilés Cachexia: a new definition Clin Nutr 27 2008 793 799
96. R.A. Fielding, B. Vellas, and W.J. Evans Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia J Am Med Dir Assoc 12 2011 249 256
97. J.E. Morley, A.M. Abbatecola, and J.M. Argiles Sarcopenia with limited mobility: an international consensus J Am Med Dir Assoc 12 2011 403 409
98. J.M. Argilés, F.J. López-Soriano, M. Toledo, A. Betancourt, R. Serpe, and S. Busquets The cachexia score (CASCO): a new tool for staging cachectic cancer patients J Cachexia Sarcopenia Muscle 2 2011 87 93
99. M. Muscaritoli, S.D. Anker, and J. Argilés Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) cachexia-anorexia in chronic wasting diseases and nutrition in geriatrics Clin Nutr 29 2010 154 159
100. K. Fearon, F. Strasser, and S.D. Anker Definition and classification of cancer cachexia: an international consensus Lancet Oncol 12 2011 489 495
101. K. Fearon, W.J. Evans, and S.D. Anker Myopenia - a new universal term for muscle wasting J Cachexia Sarcopenia Muscle 2 2011 1 3
102. V.E. Baracos Pitfalls in defining and quantifying cachexia J Cachexia Sarcopenia Muscle 2 2011 71 73
103. Alagiakrishnan K, Banach M, Jones LG, Datta S, Ahmed A, Aronow WS. Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. Ann Med in press. http://dx.doi.org/10.3109/07853890.2012. 660493.
104. D. Karasek, W. Sinkiewicz, and J. Błażejewski Relationship between B-type natriuretic peptide serum level, echocardiographic TEI index and the degree of diastolic dysfunction in patients with heart failure with preserved systolic function Arch Med Sci 7 2011 449 456
105. S. von Haehling, and S.D. Anker The 6th Cachexia Conference: an introduction to clinical and basic research in an exiting area J Cachexia Sarcopenia Muscle 2 2011 189 190